Virax Biolabs Group Limited — FY2024 Form 20-F
Reporting period: Fiscal year ended March 31, 2024; filed August 20, 2024. Although the request specifies “2023 Q4,” this is an annual report, not a standalone quarterly filing. Financial statements are audited and prepared under IFRS as issued by the IASB.
Business context
Virax is an early-stage biotechnology company developing ViraxImmune, a T-cell diagnostics and immune-profiling platform aimed at post-viral syndromes, chronic inflammation and T-cell exhaustion. Its ViraxClear and ViraxVet activities distribute third-party test kits; these generated all reported FY2024 revenue. ViraxImmune remains in development, and the company says it has not submitted clinical performance studies to a regulatory agency for approval.
Key financial metrics
| Metric (USD unless stated) | FY2024 | FY2023 |
|---|---|---|
| Revenue | $156,419 | $8,561 |
| Gross profit (loss) | $50,590 | $(1,365) |
| Gross margin | 32.3% | Negative |
| Operating expenses | $6,547,063 | $5,731,396 |
| Operating loss | $(6,496,473) | $(5,732,761) |
| Net loss | $(6,739,120) | $(5,457,763) |
| Net loss per share | $(3.36) | $(5.13) |
| Cash used in operating activities | $(6,247,016) | $(4,179,767) |
| Cash used in investing activities | $(1,164,449) | $(178,403) |
| Cash provided by financing activities | $1,648,171 | $13,688,952 |
| Cash at year-end | $3,589,244 | $9,352,538 |
At March 31, 2024, total assets were $5,483,969, current assets $4,380,252 and current liabilities $168,849. Total liabilities were $345,194, including $224,300 of operating lease liabilities; the insurance note payable was fully repaid. Accumulated deficit was $18,527,997. No income tax expense was recorded.
Changes, financing and unusual items
- Revenue rose from a small base, but remained immaterial relative to expenses. Two customers accounted for 100% of FY2024 revenue, versus one customer in FY2023.
- General and administrative expense increased to $4.59 million from $3.55 million. Research and development expense fell to $1.56 million from $2.18 million.
- The company recorded a $390,355 impairment charge, fully writing off capitalized ViraxImmune mobile-application costs after development was suspended. Investing cash outflow also included $952,497 for laboratory and computer equipment.
- Other expenses included a $210,500 legal settlement; FY2023 included a $294,383 gain on debt extinguishment. Stock-based compensation was $1,011,973, down from $1,734,601.
- Financing cash flow included approximately $1.9 million net proceeds from warrant exercises. The company had 1,546,433 warrants outstanding at year-end, with a weighted-average exercise price of $3.05.
- A 1-for-10 share consolidation took effect December 18, 2023; the company said it regained Nasdaq minimum-bid-price compliance in January 2024. Year-end ordinary shares outstanding were 2,573,903.
Liquidity, outlook and risks
The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management says current cash and future financing are expected to fund operations, but also states that significant additional capital is needed and internal cash flow is not expected to cover requirements in the foreseeable future. FY2024 operating cash use exceeded year-end cash. In June 2024, the company sold 391,017 shares through its at-the-market program for net proceeds of $754,511; the ATM agreement permits offers of up to approximately $1.46 million in aggregate. Further equity or debt financing, grants, partnerships or other funding may be required, with potential dilution or delays to business plans.
No quantified revenue, earnings or product-launch guidance is provided. Management expects continued operating losses while it funds research and development, regulatory approvals and commercialization. Key execution risks include clinical and analytical validation, regulatory clearance in target markets, market acceptance and reimbursement, competition, customer concentration, intellectual-property protection, and data privacy and cybersecurity requirements. The company also identifies PRC regulatory and currency-transfer uncertainty.
Management concluded disclosure controls and procedures were not effective as of March 31, 2024. It said the company was too small to effectively assess internal control over financial reporting; the auditor was not engaged to opine on internal-control effectiveness. The company reported no material cybersecurity incident during the fiscal year.
Most important facts for investors to verify
- Current cash, subsequent cash burn and financing needs; confirm the post-year-end ATM proceeds and any further capital raised.
- Going-concern status and the assumptions behind management’s funding plan and the auditor’s substantial-doubt conclusion.
- Warrant and option terms, potential share issuance, and current shares outstanding; the filing’s share count is as of March 31, 2024.
- ViraxImmune’s clinical-validation milestones, regulatory pathway, timing, and remaining development costs; no approved ViraxImmune product revenue is reported.
- Revenue customer concentration and whether ViraxClear/ViraxVet distribution can produce recurring, material revenue.
- Plans to address ineffective disclosure controls and the suspension and impairment of the mobile application.